Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Current Urology Reports

Volumn 17, Issue 1, 2016, Pages 1-9

  Kim, Aram ^a   Shin, Dong Myung ^a   Choo, Myung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bladder pain syndrome; Interstitial cystitis; Mesenchymal stem cell

Indexed keywords

BLADDER IRRIGATION; CAUTERIZATION; CELL REGENERATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYSTALGIA; DIAGNOSTIC TEST; HUMAN; INTERSTITIAL CYSTITIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT SAFETY; PATIENT SATISFACTION; PELVIC PAIN; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; STRATEGIC PLANNING; TREATMENT INDICATION; URINARY FREQUENCY; ANIMAL; BIOLOGICAL THERAPY; CYSTITIS, INTERSTITIAL; INTRAVESICAL DRUG ADMINISTRATION; QUALITY OF LIFE; STEM CELL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CELL- AND TISSUE-BASED THERAPY; CYSTITIS, INTERSTITIAL; HUMANS; PELVIC PAIN; QUALITY OF LIFE; STEM CELLS;

EID: 84950316897     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0563-1     Document Type: Review

References (88)

1. Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology. 2004;63(3 Suppl 1):85–92.
2. Nickel JC et al. Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study. J Urol. 2010;183(1):167–72.
3. Clemens JQ et al. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol. 2007;177(4):1390–4.
4. Lin CS. Stem cell therapy for the bladder—where do we stand? J Urol. 2011;185(3):779–80.
5. Maumus M et al. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther. 2011;2(2):14.
6. Wang D et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79.
7. Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. Urol Clin N Am. 1994;21(1):41–53.
8. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328(4):257–65.
9. Church MK et al. Mast cells, neuropeptides and inflammation. Agents Actions. 1989;27(1–2):8–16.
10. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47–55.
11. Parsons CL et al. Abnormal urinary potassium metabolism in patients with interstitial cystitis. J Urol. 2005;173(4):1182–5.
12. Liu HT, Jiang YH, Kuo HC. Alteration of urothelial inflammation, apoptosis, and junction protein in patients with various bladder conditions and storage bladder symptoms suggest common pathway involved in underlying pathophysiology. Luts-Lower Urinary Tract Symptoms. 2015;7(2):102–7.
13. Parsons CL et al. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol. 1990;143(1):139–42.
14. Parsons CL, Greenspan C, Mulholland SG. The primary antibacterial defense mechanism of the bladder. Investig Urol. 1975;13(1):72–8.
15. Parsons CL et al. Role of surface mucin in primary antibacterial defense of bladder. Urology. 1977;9(1):48–52.
16. Parsons CL et al. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998;159(6):1862–6. discussion 1866–7.
17. Chuang YC et al. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology. 2003;61(3):664–70.
18. Muchmore AV, Decker JM. Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science. 1985;229(4712):479–81.
19. Tamm I, Horsfall Jr FL. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med. 1950;74(1):106–8.
20. Parsons CL et al. Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J Urol. 2000;164(4):1381–4.
21. Stein P, Rajasekaran M, Parsons CL. Tamm-Horsfall protein protects urothelial permeability barrier. Urology. 2005;66(4):903–7.
22. Parsons CL. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int. 2011;107(3):370–5. The research focused on the mechanisms of the defected epithelium of bladder in the IC/BPS and showed the reason of pain in the patients.
23. van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4(9):484–91.
24. Martinez-Martinez LA et al. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case–control studies. J Clin Rheumatol. 2014;20(3):146–50.
25. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143(6):1118–24.
26. Harrington DS, Fall M, Johansson SL. Interstitial cystitis: bladder mucosa lymphocyte immunophenotyping and peripheral blood flow cytometry analysis. J Urol. 1990;144(4):868–71.
27. Christmas TJ. Lymphocyte sub-populations in the bladder wall in normal bladder, bacterial cystitis and interstitial cystitis. Br J Urol. 1994;73(5):508–15.
28. Bicer F et al. Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model. Am J Physiol Renal Physiol. 2015;308(2):F103–13.
29. Singh UP et al. The severity of experimental autoimmune cystitis can be ameliorated by anti-CXCL10 Ab treatment. PLoS One. 2013;8(11), e79751.
30. van de Merwe JP et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.
31. Hanno PM et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53. The AUA guideline assessed the introduced researches which were involved with the pathogenesis, diagnosis and treatments, concluding that many treatment options are effective but have some limitations.
32. Hanno PM et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70.
33. Chang FY, Lu CL. Irritable bowel syndrome and migraine: bystanders or partners? J Neurogastroenterol Motil. 2013;19(3):301–11.
34. Smorgick N et al. Prevalence of pain syndromes, mood conditions, and asthma in adolescents and young women with endometriosis. J Pediatr Adolesc Gynecol. 2013;26(3):171–5.
35. van Ophoven A et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533–6.
36. Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol. 2007;14(4):3599–607.
37. Nickel JC et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.
38. Sairanen J et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174(6):2235–8.
39. Herrmann E, van Ophoven A. Re: Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial: E. L. Davis, S. R. El Khoudary, E. O. Talbott, J. Davis and L. R. Regan J Urol 2008; 179: 177-185. J Urol. 2008;180(6):2718–9.
40. Henry RA. Re: Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. E. L. Davis, S. R. El Khoudary, E. O. Talbott, J. Davis and L. J. Regan. J Urol 2008; 179: 177–185. J Urol. 2008;180(1):411–2. author reply 412–3.
41. Kim A et al. Pretreatment features to influence effectiveness of intravesical hyaluronic acid instillation in refractory interstitial cystitis/painful bladder syndrome. Int Neurourol J. 2014;18(3):163–7.
42. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–61.
43. Ryu J et al. Elimination of Hunner’s ulcers by fulguration in patients with interstitial cystitis: is it effective and long lasting? Korean J Urol. 2013;54(11):767–71.
44. Ratajczak MZ et al. A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues. Leukemia. 2007;21(5):860–7.
45. Cheng AS, Yau TM. Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg. 2008;20(2):94–101.
46. Maltais S et al. The paracrine effect: pivotal mechanism in cell-based cardiac repair. J Cardiovasc Transl Res. 2010;3(6):652–62.
47. Gharaibeh B et al. Terminal differentiation is not a major determinant for the success of stem cell therapy—cross-talk between muscle-derived stem cells and host cells. Stem Cell Res Ther. 2011;2(4):31.
48. Ratajczak MZ et al. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 2006;20(11):1915–24.
49. Kucia M et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879–94.
50. Tsuzuki Y et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000;60(22):6248–52.
51. Morikawa S et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med. 2009;206(11):2483–96.
52. Corpechot C et al. Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol. 2002;160(2):613–20.
53. Kucia M et al. Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia. 2006;20(1):18–28.
54. Song M et al. The paracrine effects of mesenchymal stem cells stimulate the regeneration capacity of endogenous stem cells in the repair of a bladder-outlet-obstruction-induced overactive bladder. Stem Cells Dev. 2014;23(6):654–63.
55. Wezel F, Southgate J, Thomas DF. Regenerative medicine in urology. BJU Int. 2011;108(7):1046–65.
56. Zhao W et al. Periurethral injection of autologous adipose-derived stem cells with controlled-release nerve growth factor for the treatment of stress urinary incontinence in a rat model. Eur Urol. 2011;59(1):155–63.
57. Huang YC et al. Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model. J Urol. 2010;183(3):1232–40.
58. Zhang H et al. Adipose tissue-derived stem cells ameliorate diabetic bladder dysfunction in a type II diabetic rat model. Stem Cells Dev. 2012;21(9):1391–400.
59. Woo LL et al. Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. J Urol. 2011;185(3):1132–8.
60. Song YS et al. Mesenchymal stem cells overexpressing hepatocyte growth factor (HGF) inhibit collagen deposit and improve bladder function in rat model of bladder outlet obstruction. Cell Transplant. 2012;21(8):1641–50.
61. Adamowicz J, Pokrywczynska M, Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med Hypotheses. 2014;82(6):670–3.
62. Song M et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57. The research showed the therapeutic effects and mechanisms of mesenchymal stem cell therapy in animal model of interstitial cystitis.
63. Westropp JL, Buffington CA. In vivo models of interstitial cystitis. J Urol. 2002;167(2 Pt 1):694–702.
64. Shin K et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110–4.
65. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001;20(5):645–53.
66. Sordella R et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163–7.
67. Chen YT et al. Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial cystitis in rat. J Pineal Res. 2014;57(3):248–61. The report revealed that combination of melatonin and mesenchymal stem cell significantly improved interstitial cystitis.
68. Thomson JA et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7.
69. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.
70. Tachibana M et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell. 2013;153(6):1228–38.
71. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.
72. Wernig M et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448(7151):318–24.
73. Wang CH et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol. 2008;28(1):54–60.
74. Westerweel PE, Verhaar MC. Directing myogenic mesenchymal stem cell differentiation. Circ Res. 2008;103(6):560–1.
75. Minguell JJ, Allers C, Lasala GP. Mesenchymal stem cells and the treatment of conditions and diseases: the less glittering side of a conspicuous stem cell for basic research. Stem Cells Dev. 2013;22(2):193–203.
76. Montzka K, Heidenreich A. Application of mesenchymal stromal cells in urological diseases. BJU Int. 2010;105(3):309–12.
77. Bianco P et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19(1):35–42.
78. Jaing TH. Umbilical cord blood: a trustworthy source of multipotent stem cells for regenerative medicine. Cell Transplant. 2014;23(4–5):493–6.
79. Damien P, Allan DS. Regenerative therapy and immune modulation using umbilical cord blood-derived cells. Biol Blood Marrow Transplant. 2015;21(9):1545–54.
80. Nayoun K, Seok-Goo C. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J Stem Cells. 2015;8(1):54–68.
81. Liang X et al. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2014;23(9):1045–59.
82. Kucia M et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4(+) stem cells identified in adult bone marrow. Leukemia. 2006;20(5):857–69.
83. Kim Y et al. The molecular nature of very small embryonic-like stem cells in adult tissues. Int J Stem Cells. 2014;7(2):55–62.
84. Schwartz SD et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012;379(9817):713–20.
85. Schwartz SD et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509–16.
86. Moon SH et al. Differentiation of hESCs into mesodermal subtypes: vascular-, hematopoietic- and mesenchymal-lineage cells. Int J Stem Cells. 2011;4(1):24–34.
87. Lee MO et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A. 2013;110(35):E3281–90.
88. Kang H et al. The therapeutic effects of human mesenchymal stem cells primed with sphingosine-1 phosphate on pulmonary artery hypertension. Stem Cells Dev. 2015;24(14):1658–71.